CYCN
Cyclerion
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CYCN
Cyclerion Therapeutics, Inc.
A clinical-stage biopharmaceutical company that develops and commercializes treatments for serious and orphan diseases
245 First Street, 18th Floor, Cambridge, Massachusetts 02142
--
Cyclerion Therapeutics, Inc., was incorporated in Massachusetts on September 6, 2018. Cyclerion is a biopharmaceutical company focused on the use of novel soluble guanylate cyclase stimulators in the central nervous system and peripheral for the treatment of serious diseases. The nitric oxide sGC cyclic guanosine monophosphate signaling pathway is the fundamental mechanism for precise control of key aspects of systemic physiology. The NO-SGC-cGMP pathway regulates a variety of key biological functions of the CNS and the periphery and has been successfully targeted by several drugs.
Company Financials
EPS
CYCN has released its 2023 Q3 earnings. EPS was reported at -2.12, versus the expected 0, missing expectations. The chart below visualizes how CYCN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CYCN has released its 2025 Q1 earnings report, with revenue of 81.00K, reflecting a YoY change of NaN%, and net profit of -1.43M, showing a YoY change of 7.33%. The Sankey diagram below clearly presents CYCN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
